Targeted therapy that inhibits the interaction between HK and gC1qR, such as the 74.5.2 mAb, has attenuated bradykinin-associated permeability changes in endothelial cells (Fandaros et al., 2022), a promising finding that offers a potential therapeutic target for post-stroke edema management. The gene discussed is C1QBP; the disease is Stroke.